Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Apr 7, 2026

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

Reply: To PMID 26142586

Gregory A Joice¹, Max Kates¹, Trinity J Bivalacqua¹

¹James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins School of Medicine, Baltimore, MD.

|July 6, 2015

Summary

No abstract available in PubMed .

More Related Videos

A Bright NIR-II Fluorescence Probe for Vascular and Tumor Imaging

A Bright NIR-II Fluorescence Probe for Vascular and Tumor Imaging

Published on: March 17, 2023

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Related Experiment Videos

Last Updated: Apr 7, 2026

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

A Bright NIR-II Fluorescence Probe for Vascular and Tumor Imaging

A Bright NIR-II Fluorescence Probe for Vascular and Tumor Imaging

Published on: March 17, 2023

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Assessing Human Epidermal Growth Factor Receptor 2 in Urothelial Carcinoma: Insights From Clinical Practice Into Scoring Criteria, Histologic Subtypes, and Genomic Characteristics Across Disease Sites.

Archives of pathology & laboratory medicine·2026

Same author

Early Efficacy and Exploratory Biomarker Data of Bel-sar in Patients with Intermediate-risk and High-risk Non-muscle-invasive Bladder Cancer.

European urology open science·2026

Same author

Reply by Authors.

The Journal of urology·2026

Same author

'BJUI Clinical Dilemma': Recurrent high-grade non-muscle-invasive bladder cancer in 2026.

BJU international·2026

Same author

Optimizing ChatGPT: Applying prompt engineering to frequently asked questions in urologic oncology.

Canadian Urological Association journal = Journal de l'Association des urologues du Canada·2026

Same author

UGN-102 for Recurrent Low-Grade Intermediate-Risk Non-Muscle-Invasive Bladder Cancer: A 24-Month Duration of Response Results From the Phase 3 ENVISION Trial.

The Journal of urology·2026

Same journal

Editorial Comment on "A Histopathologic Assessment of Prostate Ductal Anatomy in Relation to Micro-Ultrasound".

Urology·2026

Same journal

Same-Day Discharge Following Multiport Robot-Assisted Simple Prostatectomy: A Prospective Feasibility Study of Outcomes, Costs, and Post-Discharge Healthcare Utilization.

Urology·2026

Same journal

Extended versus Standard Lymph Node Dissection at the Time of Radical Cystectomy for Bladder Cancer.

Urology·2026

Same journal

Intractable Epistaxis and Severe Hypertension in a Young Woman.

Urology·2026

Same journal

A 53-Year-Old Man with Elevated PSA and a Cystic Pelvic Lesion.

Urology·2026

Same journal

Low-Grade, Papillary Bladder Tumors A plea for in-office fulguration.

Urology·2026

See all related articles